By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Merrimack Pharmaceuticals Inc. 

101 Binney Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-441-1000 Fax: 617-491-1386


SEARCH JOBS



Segment
Start Up

Collaborations

Dyax Corp.  Antibody phage display





Company News
Merrimack Pharmaceuticals Inc. (MACK) Announces The Addition Of Russell T. Ray To Its Board Of Directors 12/17/2014 8:01:49 AM
Merrimack Pharmaceuticals Inc. (MACK) Presents Research On Innovative Pipeline For Patients With Breast Cancer At The 2014 San Antonio Breast Cancer Symposium 12/12/2014 7:33:29 AM
Merrimack Pharmaceuticals Inc. (MACK) To Present At Oppenheimer 25th Annual Healthcare Conference, Hold Analyst Day And Present Research On Multiple Molecules In December 2014 12/3/2014 4:01:30 PM
Merrimack Pharmaceuticals Inc. (MACK) Presents On Multiple Programs At The 26th European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research Symposium On Molecular Targets And Cancer Therapeutics 11/21/2014 2:46:31 PM
PharmaEngine Announces The Receipt Of US FDA Fast Track Designation For MM-398 In Post-Gemcitabine Metastatic Pancreatic Cancer By Merrimack Pharmaceuticals Inc. (MACK) 11/20/2014 5:53:40 AM
Merrimack Pharmaceuticals Inc. (MACK) Receives FDA Fast Track Designation For MM-398 In Post-Gemcitabine Metastatic Pancreatic Cancer 11/19/2014 9:22:59 AM
Photo Release -- Merrimack Pharmaceuticals Inc. (MACK) Announces The Addition Of Vivian S. Lee, Dean Of University Of Utah School Of Medicine, To Its Board Of Directors 11/17/2014 2:42:24 PM
Merrimack Pharmaceuticals Inc. (MACK) To Present Advances On Targeted Cancer Molecules At The 2014 American Association for Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer International Conference 11/14/2014 10:14:09 AM
Merrimack Pharmaceuticals Inc. (MACK) Reports Third Quarter 2014 Financial Results 11/11/2014 7:55:10 AM
Merrimack Pharmaceuticals Inc. (MACK) Announces Initiation Of Phase 1 Clinical Study Of MM-398 For Brain Cancer 11/6/2014 7:21:09 AM
12345678910...
//-->